ElevateBio

The difference speaks for itself. From precise gene-editing tools to AI-driven design, ElevateBio’s robust capabilities support partners’ advanced therapies across the full product lifecycle. Explore what sets us apart: bit.ly/42b7xBH

We're presenting at the International Society for Cell & Gene Therapy held from May 6-9. Chesney Michels will discuss "A Novel Non-Viral Platform Combining a LEG Nuclease and mbDNA™ for High-Efficiency T-Cell Engineering." Learn more about ISCT: bit.ly/4tQf0lO

We’re sharing new gene editing capabilities at @ASGCTherapy. ElevateBio will deliver 9 presentations demonstrating the breadth of our genetic medicine platform. Learn more: bit.ly/4t72mOi

We offer three structured partnership models that reflect how R&D teams move programs forward. Each path addresses a distinct stage of decision-making. Learn more about the three paths to therapeutic progress: bit.ly/4sKGIil

Through AI, we’re accelerating the development of potentially curative treatments across a broad range of therapeutic areas, drastically cutting timelines on the path towards the clinic. Learn more: bit.ly/3NPycAu

At @ASGCTherapy, we're highlighting our genetic medicine platform: AI-powered discovery, data from emerging editing modalities, protein engineering expertise, off-target assessment strategies, & our non-viral delivery platform. Read the press release: bit.ly/4edwpQy

Ron Chong & Sarah Compton will lead Engineering Precision in Genetic Medicines, a webinar hosted by @OutsourcedPharm to explore how engineering assays, generative AI, & directed evolution can expand the range of addressable diseases. Register: bit.ly/4eD50HL

Cell therapy manufacturing is complex. Learn the 10 questions to ask when choosing a cell therapy CDMO. Read more: bit.ly/4tndBmf

ElevateBio partners with innovators to identify drug targets & manufacture clinical & commercial products to address unmet medical needs. Our capabilities span the full development journey, so your program never has to restart with someone new. Learn more: bit.ly/4tc23Cu

Our team is headed to the 2026 Cell & Gene Meeting on the Med. Chief Scientific Officer, Amy Pooler, Ph.D., will present on how ElevateBio supports partners in designing, developing, & manufacturing therapies from early discovery through commercialization. bit.ly/3ODaho5

Our Proof-of-Concept partnership model is designed to answer a foundational development question: can the right gene edit be made for this target? Learn more about our flexible partnership models at bit.ly/4cMA72h

We're headed to Copenhagen for #CRISPRMED26. Adrian Oliver, Associate Director, Translational Biology, will discuss how ElevateBio has identified editing systems that demonstrated near complete knockdown of the target gene 𝘪𝘯 𝘷𝘪𝘷𝘰. Register here: bit.ly/3PUthPk

Step inside our manufacturing facility designed to take your therapies from discovery to commercialization. By housing all capabilities under one roof, we streamline the manufacturing process across the entire product lifecycle. Explore more: bit.ly/4m1ZZtT

ElevateBio partners get a close-up look at our BaseCamp® facilities, from laboratories to manufacturing suites. Being present in the space alongside our own team builds trust and strengthens collaboration at every stage. Explore BaseCamp®: bit.ly/commercial-man…

Katie Shannon, VP, Site Head at BaseCamp® Pittsburgh, shares her perspective on what makes Pittsburgh a natural home for our new biomanufacturing facility in our latest Elevated Insights article: bit.ly/4bhALnJ

Many manufacturing setbacks don’t start in the cleanroom. They start upstream—in planning, systems, and visibility. This whitepaper explores how ElevateBio builds reliability into cell therapy manufacturing. Read more here: bit.ly/4b3huVH

ElevateBio is a first-of-its-kind genetic medicine company with integrated manufacturing & technology stack. We help partners realize the potential of their therapies from concept to cure. Learn more: bit.ly/4suC34x

Commercial readiness is a quality system decision. From contamination control to inspection-ready operations & integrated quality systems, we support cell & gene therapy programs so you can move confidently toward commercialization. Read the whitepaper: bit.ly/4rYE6hq

Today is International Women’s Day, and we’re celebrating the women driving discovery and advancing cutting-edge science. Whether inside the labs, across our offices, or on the manufacturing floor, women at ElevateBio are transforming the future of medicine.

Jeff Cram, VP, Process Development will present at Outsourced Pharma Capabilities Update. He will discuss how our process development capabilities & expertise accelerate the development of advanced therapies. Register: bit.ly/40cg2eN